Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00349492 | A Study Comparing Etoposide/Cisplatin With Irinotecan/Cisplatin to Treat Extensive Disease Small Lung Cancer | PHASE3 | COMPLETED | 372 | — | — | Jun 1, 2006 | Oct 1, 2013 | Dec 4, 2013 | 14 | South Korea |
| Arm | Type | Description |
|---|---|---|
| EP | ACTIVE_COMPARATOR | etoposide + cisplatin |
| Name | Type | Description |
|---|---|---|
| IP | DRUG | irinotecan+cisplatin |
Inclusion Criteria: * Histologically or cytologically diagnosed small cell lung cancer * Extensive disease (distant metastasis, contralateral hilar lymph node involvement, or cytologically confirmed malignant pleural effusion) * If patients have brain metastasis with neurological symptom, they shou...